CytoSorbents Corporation

CytoSorbents Corporation is a New Jersey-based company that specializes in blood purification technologies for critical care and cardiac surgery. Their innovative approach utilizes biocompatible, highly porous polymer beads to effectively remove toxic substances and inflammatory agents from blood and bodily fluids. This technology is particularly beneficial in intensive care units and during cardiac procedures. The company's flagship product, CytoSorb, is an extracorporeal cytokine filter that helps reduce excessive inflammation in critically ill patients by filtering blood outside the body. It is compatible with standard hospital equipment like dialysis machines and heart-lung machines, and is used in various critical conditions such as sepsis, trauma, and liver failure. In addition to CytoSorb, CytoSorbents offers products like PuriFi, ECOS, and VetResQ, which cater to different medical needs, including veterinary applications. CytoSorbents is publicly traded on NASDAQ under the ticker CTSO and is focused on advancing its product pipeline, including preparations for FDA decisions on new therapies. The company is dedicated to improving patient outcomes and addressing unmet needs in critical care medicine.

• Employees 150
• Founded 2012
• Annual Revenue $32705000
• Total Funding $56550000